4640 SW Macadam Avenue
About AbSciAbSci is a global leader in cutting-edge protein production technologies committed to reducing costs in the biopharmaceutical industry. AbSci’s technology enables dramatic reductions in the cost of producing novel and existing biologics, acceleration of drug discovery timelines, and increased efficiency and flexibility throughout the manufacturing process.
Founders: Mark Valasek and Phil Barish
CEO: Sean McClain
Please click here for AbSci job opportunitites.
16 articles with AbSci
Financing to accelerate first mover advantage of Protein Printing™ technology which enables revolutionary efficiencies in protein manufacturing
AbSci CEO Sean McClain Named as an Entrepreneur Of The Year® 2020 Pacific Northwest Region Award Winner
AbSci announced that Sean McClain, founder and CEO of AbSci, was named as an Entrepreneur Of The Year® 2020 Pacific Northwest Region Award winner.
AbSci, the Protein Printing™ company, is pleased to announce the appointment of Greg Schiffman, CPA as Chief Financial Officer.
AbSci Closes $15.4 M in Series D Funding to Accelerate Growth and Scale Disruptive Protein PrintingTM Technology, Announces Exclusive Co-Marketing Partnership with KBI Biopharma
AbSci announced the completion of a $10.4M Series D financing led by KBI Biopharma and JSR Life Sciences.
There is, thankfully, no age limit on innovation—you can do it at any age. But for many, “young,” counts as under 30, sometimes under 35, or even under 40, at least in terms of putting together lists of scientific innovators.
AbSci Develops Game-Changing 12-Week Cell Line Optimization Workflow and Adds Two New Members to Its Executive Team
Martina Molsbergen, Vice President, Business Development and Johan Kers, PhD, Vice President, Research.
AbSci, a global leader in biotherapeutic discovery and manufacturing technologies, today announced a collaboration with Sanofi.
AbSci Raises Oversubscribed $12M Series C to Fuel Commercialization of Its Groundbreaking Protein Expression Platform
The Series C Round led by Asahi Glass Co., Ltd. "AGC" includes participation from all prior investors (Phoenix Venture Partners, Oregon Venture Fund, WRF Capital, and Souther Co.) and new investors Columbia Ventures Corporation and GreenBridge.
AbSci, announced the addition of Coherus' CSO, Alan Herman, PhD to its Scientific Advisory Board.
A pioneer of the biotech industry, Dr. Bennett brings his decades of experience in downstream process development, protein purification, and regulatory affairs to the AbSci team.
Prior to formally joining AbSci's Scientific Advisory Board, Dr. Larimore advised AbSci on various aspects of biopharmaceutical process development manufacturing scale-up.